Hikma Pharmaceuticals Plc (HIK) Given Average Rating of “Hold” by Brokerages
Shares of Hikma Pharmaceuticals Plc (LON:HIK) have been assigned an average rating of “Hold” from the eleven ratings firms that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is GBX 1,574.18 ($20.33).
A number of research analysts recently commented on the stock. J P Morgan Chase & Co reaffirmed a “neutral” rating and issued a GBX 1,500 ($19.37) price target (down previously from GBX 1,800 ($23.25)) on shares of Hikma Pharmaceuticals Plc in a report on Monday, May 22nd. Numis Securities Ltd reaffirmed an “add” rating and issued a GBX 1,560 ($20.15) price target on shares of Hikma Pharmaceuticals Plc in a report on Thursday, August 17th. HSBC Holdings plc lowered their price target on shares of Hikma Pharmaceuticals Plc from GBX 1,700 ($21.96) to GBX 1,410 ($18.21) and set a “reduce” rating for the company in a report on Tuesday, June 27th. Jefferies Group LLC reaffirmed an “underperform” rating and issued a GBX 1,450 ($18.73) price target on shares of Hikma Pharmaceuticals Plc in a report on Friday, June 2nd. Finally, Goldman Sachs Group, Inc. (The) downgraded shares of Hikma Pharmaceuticals Plc to a “neutral” rating and lowered their price target for the company from GBX 2,600 ($33.58) to GBX 1,310 ($16.92) in a report on Tuesday, August 22nd.
TRADEMARK VIOLATION NOTICE: This report was posted by American Banking News and is owned by of American Banking News. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://www.americanbankingnews.com/2017/09/16/hikma-pharmaceuticals-plc-hik-given-average-rating-of-hold-by-brokerages.html.
Shares of Hikma Pharmaceuticals Plc (HIK) opened at 1202.00 on Friday. The stock has a 50 day moving average price of GBX 1,275.00 and a 200-day moving average price of GBX 1,652.60. The company’s market cap is GBX 2.88 billion. Hikma Pharmaceuticals Plc has a 1-year low of GBX 1,101.00 and a 1-year high of GBX 2,346.00.
Hikma Pharmaceuticals Plc Company Profile
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The Company’s segments include Branded, Injectables, Generics and Others. It sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.